Clonally related but phenotypically divergent human cancer cell lines derived from a single follicular thyroid cancer recurrence (TT2609)

被引:14
作者
Geldof, AA
Versteegh, RT
van Mourik, JC
Rooimans, MA
Arwert, F
Hermsen, MAJA
Schadee-Eestermans, IL
van Dongen, GAMS
van der Valk, P
Clement, EHV
Lips, P
Teule, GJJ
机构
[1] Vrije Univ Hosp, Dept Nucl Med, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Hosp, Dept Surg, Amsterdam, Netherlands
[3] Vrije Univ Hosp, Dept Anthropogenet, Amsterdam, Netherlands
[4] Vrije Univ Hosp, Dept Pathol, Amsterdam, Netherlands
[5] Vrije Univ Hosp, Dept Cell Biol, Amsterdam, Netherlands
[6] Vrije Univ Hosp, Dept Otolaryngol, Amsterdam, Netherlands
[7] Vrije Univ Hosp, Dept Endocrinol, Amsterdam, Netherlands
[8] Vrije Univ Amsterdam, Sch Med, Amsterdam, Netherlands
关键词
D O I
10.1089/105072501753210966
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Starting from different regional samples taken from a heterogeneous follicular thyroid cancer recurrence in a male patient, a series of cell cultures was initiated. Three stable cancer cell lines were successfully established (TT2609-A02, TT2609-B02, and TT2609-C02) and kept in continuous culture for more than 3 years. The lines are each characterized by a unique set of biological parameters such as morphology, ploidy state, cell proliferation rate, ultrastructure, thyroid marker expression, p53 expression, karyogram, agar clonogenic capacity and tumorigenicity as xenografts in nude mice. These characterization studies point to a marked heterogeneity at the level of the clinical tumor recurrence. Karyotype analysis of the cell lines showed a pattern of aberrations indicating that the lines are clonally related and that the A02 and C02 lines are subsequently derived from the more "original" tumor cell type B02 after a tetraploidization event. It is concluded that the obtained cell lines represent an in vitro/in vivo model for human follicular thyroid cancer. The availability of a series of cell lines for human follicular thyroid cancer, mimicking the biological heterogeneity observed in patient tumors, enables both detailed fundamental investigation of thyroid cancer cell biology and the experimental exploration of new treatment approaches.
引用
收藏
页码:909 / 917
页数:9
相关论文
共 30 条
[11]   ABERRANT EXPRESSION OF RECEPTORS FOR PLATELET-DERIVED GROWTH-FACTOR IN AN ANAPLASTIC THYROID-CARCINOMA CELL-LINE [J].
HELDIN, NE ;
GUSTAVSSON, B ;
CLAESSONWELSH, L ;
HAMMACHER, A ;
MARK, J ;
HELDIN, CH ;
WESTERMARK, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (23) :9302-9306
[12]  
Hermsen MAJA, 1996, GENE CHROMOSOME CANC, V15, P1
[13]   CYTOGENETIC AND MOLECULAR GENETIC-STUDIES OF FOLLICULAR AND PAPILLARY THYROID CANCERS [J].
HERRMANN, MA ;
HAY, ID ;
BARTELT, DH ;
RITLAND, SR ;
DAHL, RJ ;
GRANT, CS ;
JENKINS, RB .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (05) :1596-1604
[14]   EPIDERMAL GROWTH-FACTOR ENHANCES PROLIFERATION, MIGRATION, AND INVASION OF FOLLICULAR AND PAPILLARY THYROID-CANCER IN-VITRO AND IN-VIVO [J].
HOELTING, T ;
SIPERSTEIN, AE ;
CLARK, OH ;
DUH, QY .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (02) :401-408
[15]  
Hoelting Thomas, 1994, Journal of Clinical Endocrinology and Metabolism, V79, P806
[16]  
JENKINS RB, 1990, CANCER-AM CANCER SOC, V66, P1213, DOI 10.1002/1097-0142(19900915)66:6<1213::AID-CNCR2820660622>3.0.CO
[17]  
2-9
[18]   Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines [J].
Jossart, GH ;
Epstein, HD ;
Shaver, JK ;
Weier, HU ;
Greulich, KM ;
Tezelman, S ;
Grossman, RF ;
Siperstein, AE ;
Duh, QY ;
Clark, OH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) :3498-3504
[19]  
KOHN LD, 1989, INT CONGR SER, V818, P243
[20]   All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1 [J].
Kurebayashi, J ;
Tanaka, K ;
Otsuki, T ;
Moriya, T ;
Kunisue, H ;
Uno, M ;
Sonoo, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08) :2889-2896